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AbsTrACT
background critically ill patients with impaired 
neutrophil phagocytosis have significantly increased 
risk of nosocomial infection. granulocyte-macrophage 
colony-stimulating factor (gM-cSF) improves 
phagocytosis by neutrophils ex vivo. this study tested 
the hypothesis that gM-cSF improves neutrophil 
phagocytosis in critically ill patients in whom 
phagocytosis is known to be impaired.
Methods this was a multicentre, phase iia randomised, 
placebo-controlled clinical trial. Using a personalised 
medicine approach, only critically ill patients with 
impaired neutrophil phagocytosis were included. Patients 
were randomised 1:1 to subcutaneous gM-cSF (3 μg/
kg/day) or placebo, once daily for 4 days. the primary 
outcome measure was neutrophil phagocytosis 2 days 
after initiation of gM-cSF. Secondary outcomes included 
neutrophil phagocytosis over time, neutrophil functions 
other than phagocytosis, monocyte Hla-Dr expression 
and safety.
results thirty-eight patients were recruited from 
five intensive care units (17 randomised to gM-cSF). 
Mean neutrophil phagocytosis at day 2 was 57.2% (SD 
13.2%) in the gM-cSF group and 49.8% (13.4%) in the 
placebo group, p=0.73. the proportion of patients with 
neutrophil phagocytosis≥50% at day 2, and monocyte 
Hla-Dr, appeared significantly higher in the gM-cSF 
group. neutrophil functions other than phagocytosis did 
not appear significantly different between the groups. 
the most common adverse event associated with gM-
cSF was fever.
Conclusions gM-cSF did not improve mean neutrophil 
phagocytosis at day 2, but was safe and appeared 
to increase the proportion of patients with adequate 
phagocytosis. the study suggests proof of principle for a 
pharmacological effect on neutrophil function in a subset 
of critically ill patients.
InTroduCTIon
Secondary infections acquired in the intensive care 
unit (ICU) significantly increase the risk of death in 
critically ill patients.1 2 Over 700 000 hospital-ac-
quired infections are estimated to occur annually in 
acute care hospitals in the USA,3 and infection is 
more common in ICU than in other hospital areas.
Point prevalence surveys of patients in ICU esti-
mate that approximately 70% are prescribed anti-
biotics at any time.4 High use of antibiotics exerts 
a selection pressure favouring the emergence of 
antibiotic-resistant pathogens, which are commonly 
isolated in ICU-acquired infections (ICUAI).5 
Furthermore, recent data suggest that overuse of 
antibiotics in ICUs may be associated with increased 
mortality.6 7 At a time when few effective novel anti-
biotics are emerging for use in clinical practice,8 
there is a pressing need to develop non-antibiot-
ic-based strategies for the prevention and treatment 
of ICUAI.
Neutrophils are the key cellular effectors in 
clearance of bacterial and fungal infections.9 10 
Acquired neutrophil dysfunction is common during 
critical illness. We previously showed that impair-
ment of neutrophil phagocytosis was inde-
pendently associated with significantly increased 
risk of ICUAI.11 The phagocytic dysfunction is 
consistently and significantly improved by ex vivo 
Key messages
What is the key question?
 ► Acquired impairment of phagocytosis by 
neutrophils in critically ill patients predicts the 
development of new infection, and is reversed 
by granulocyte-macrophage colony-stimulating 
factor (GM-CSF) ex vivo, but trials have not 
tested whether GM-CSF restores neutrophil 
phagocytosis in patients.
What is the bottom line?
 ► GM-CSF did not improve mean neutrophil 
phagocytosis, but was safe and increased 
the proportion of patients with adequate 
phagocytosis.
Why read on?
 ► There is a pressing need to develop non-
antibiotic-based treatments to reduce infection 
in critically ill patients, and this ‘personalised 
medicine’ trial is arguably the first to target 
patients known to be at highest risk of infection 
as a consequence of neutrophil dysfunction.
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application of granulocyte-macrophage colony-stimulating 
factor (GM-CSF).11 12 GM-CSF is used in clinical practice to 
stimulate myelopoiesis after administration of chemotherapy, 
and has been safely administered to critically ill patients.13–17
This study therefore sought to test the hypothesis that 
GM-CSF would improve neutrophil phagocytosis in critically ill 
patients. Increasing evidence points to the value of identifying 
treatment-responsive endotypes in clinical trials.18 We used a 
precision medicine approach to target patients with objectively 
demonstrated impairment of neutrophil phagocytosis, repre-
senting those at highest risk of ICUAI.11
MeThods
Patients
Patients were considered eligible if they met all of the following 
criteria: systemic inflammatory response syndrome on admis-
sion to ICU;19 recruited within 72 hours of ICU admission; has 
required support of one or more organ systems (intubation with 
mechanical ventilation, inotropic support or haemofiltration); 
expected to survive for at least 48 hours from randomisation 
(in the opinion of the ICU clinician); and neutrophil phago-
cytic capacity of <50% (the assay is described below). Exclusion 
criteria are shown in the online supplemental data section (table 
S1).
Informed, written consent was obtained from the patient or, 
where they lacked capacity, from a personal legal representative. 
When no personal legal representative was available, written 
consent was obtained from a professional legal representative, 
under the terms of our ethical approval.
randomisation
Patients were randomised 1:1, with stratification by site, using a 
web-based randomisation service in the Newcastle Clinical Trials 
Unit. Randomisation was carried out in permuted blocks of vari-
able length.
study drug
The study compared recombinant human GM-CSF derived 
from yeast (Leukine, sargramostim, purchased from Genzyme) 
reconstituted with sterile water (1 mL sterile water per 250 μg 
phial of lyophilised GM-CSF), and equivalent volume of placebo 
(normal saline) according to the patient’s weight. Both appeared 
as clear, colourless liquids. Research nurses unblinded to alloca-
tion administered GM-CSF and placebo by subcutaneous injec-
tion. Patients, medical staff, nursing staff providing clinical care 
and laboratory staff were blinded to allocation. Administration 
was once daily for 4 days, and injection sites were different every 
day. The dose of GM-CSF was 3 μg/kg/day.
sampling schedule
Whole blood was drawn at baseline (pretreatment), then daily 
through to day 9 for safety analysis. An extra 25 mL of blood 
was taken at baseline and on day 2, day 4/5, day 6/7 and day 8/9 
for functional assays (neutrophil phagocytosis and other innate 
immune cellular parameters, as described below).
Laboratory assays
Blood samples were transported fresh to a single central labora-
tory (journey time less than 1 hour from each ICU) for analysis by 
staff proficient in all of the techniques described below. Patients’ 
neutrophils were isolated from citrated whole blood by dextran 
sedimentation and discontinuous Percoll gradient.20 Neutrophil 
phagocytosis was quantified as the percentage of neutrophils 
ingesting  ≥2 zymosan  particles  (derived  from  the  cell  wall  of 
the yeast Saccharomcyes cerevisiae), which were opsonised using 
serum from the same patient whose neutrophils were being 
assessed.11 Neutrophils were incubated with serum-opsonised 
zymosan particles for 30 min and the proportion ingesting two 
or more particles was determined at light microscopy.
Neutrophil chemotaxis in response to formyl-methionine-leu-
cine-phenylalanine was estimated using the subagarose method,21 
and superoxide generation using a cytochrome c reduction 
assay.22 Neutrophil apoptosis was measured by flow cytometric 
analysis of annexin V and propidium iodide in whole blood.23 
Monocyte HLA-DR expression in whole blood was estimated by 
flow cytometry using a Quantibrite kit (BD Biosciences, Oxford, 
UK).24 Concentrations of interleukin (IL) 1β, IL-6, IL-8, IL-10, 
IL-12p70, TNFα and GM-CSF were determined by cytometric 
bead array (Becton Dickinson). All flow cytometry was carried 
out using a FACSCanto II flow cytometer (Becton Dickinson).
outcome measures
The primary outcome was neutrophil phagocytic capacity 2 
days after the first dose of GM-CSF/placebo (measured as the 
percentage  of  neutrophils  ingesting  ≥2 zymosan  particles  ex 
vivo).11 Secondary outcome measures were serial assessment 
of neutrophil phagocytosis over 9 days, and quantification of 
other neutrophil functions such as apoptosis, chemotaxis and 
superoxide generation. Monocyte HLA-DR expression was also 
assessed. Clinical and safety outcomes included serial estimation 
of sequential organ failure assessment (SOFA) Score,25 length of 
stay in ICU, the incidence of ICUAI, all-cause mortality 30 days 
postrandomisation, and laboratory analyses including full blood 
count, urea and creatinine, and aminotransferases.
safety, serious adverse events (sAes) and mortality
Safety was monitored by the trial’s data monitoring and ethics 
committee. Due to the high mortality expected in the critically 
ill population studied, the trial protocol stipulated that deaths 
should be included as SAEs only when unexpected and poten-
tially related to study drug.
sample size and statistics
Sample size was calculated from previous data analysing the 
effects of GM-CSF on ex vivo phagocytosis in critically ill 
patients.11 The mean rate of ‘neutrophils ingesting ≥2 zymosan 
particles' in ICU patients was 39% (SD 13%).11 An absolute 
increase of at least 15% (ie, from 39% to 54% mean phago-
cytosis) was considered clinically important, on the basis that 
phagocytosis of ≥50%  is  associated with  less  ICUAI,  and  that 
phagocytosis rates are rarely less than 30% or greater than 
90% using this technique. Therefore, an absolute rise of 15% 
represents a relative rise of 25% across the range of ‘commonly 
observed’ phagocytosis rates using our assay. A sample size of 17 
in each group gave power of 90% to detect this difference with 
a significance level of 0.05 using the two-sample t-test. To allow 
for an attrition rate of approximately 10% we proposed a final 
sample size of 38 patients (19 per group).
Data were analysed by TC and TF (study statisticians). The 
study’s statistical analysis plan is found at the end of the online 
supplemental data section. All authors had access to the primary 
clinical trial data. We reported descriptive statistics with CIs. 
The primary end point was analysed initially using a two-sample 
t-test, and using analysis of covariance in order to allow for the 
effects of baseline characteristics.
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We analysed change from baseline to other secondary time 
points (day 4/5, day 6/7 and day 8/9) for the primary outcome 
variable in the same way as the primary end point. Other 
secondary outcomes were examined using the same methods as 
for the primary end point.
Fisher’s exact test was used in place of the Χ2 test due to the 
small numbers in the groups. Area under the curve (AUC) was 
calculated using the linear trapezoidal rule by summing the areas 
between each time point. In cases where there were missing data 
with no additional data either before or after the missing time 
point, we did not calculate the area and treated that patient’s 
AUC as missing.
Bonferroni’s post hoc correction was used as an informal 
guide to assess significance or otherwise of the resulting p values.
Primary and secondary outcomes were assessed on an inten-
tion-to-treat basis. All analyses were repeated on a per protocol 
basis for participants who received at least two doses of treat-
ment. SAEs were recorded but not subjected to formal statistical 
analysis beyond tabulation by group.
Data with missing observations (other than due to mortality) 
were examined to determine both the extent of, and reason for, 
such omissions. For the primary outcome measure, there were 
two missing values. As the missing values are less than 10%, no 
imputation was carried out.
regulatory approvals
The study was registered on publicly accessible databases before 
the trial commenced (relevant registration numbers are  Clini-
calTrials. gov NCT01653665, ISRCTN95325384). There was 
one amendment after the trial commenced but prior to any 
patient being randomised. This amendment was to undertake 
a double-blinded rather than a single-blinded trial (reference 
number 15-09/10/2013).
resuLTs
Recruitment ran from November 2013 to February 2015 in five 
ICUs across four hospitals. The study Consolidated Standards 
of Reporting Trials diagram is shown in figure 1. All admis-
sions to each ICU were prescreened for eligibility. A total of 
444 patients meeting the trial inclusion criteria were screened 
for eligibility. Of these, 44 patients declined to give consent for 
participation and 336 were found to be ineligible on the basis 
of triggering an exclusion criterion or for another reason docu-
mented in the online supplemental data section, table S2. Of the 
64 eligible patients providing consent, 26 were excluded prior 
to randomisation, of whom 19 were found to have phagocytic 
capacity ≥50%. Seventeen patients were randomised to receive 
GM-CSF and 21 to receive placebo. The imbalance in the allo-
cation ratio was due to the use of block randomisation and 
stratification.
After an audit of data collection, it became apparent that 
unblinded nursing staff involved in the administration of the 
study drug had also undertaken the task of transferring blinded 
clinical data from source data to the electronic case report form. 
This had occurred at two of the study sites. Laboratory staff 
analysing neutrophil outcome measures (including the primary 
end point) remained blinded at all points and there was no 
evidence to suggest that this was breached at any stage. On this 
basis, while the study was intended to be double-blinded, we 
report it as a single-blinded RCT.
Baseline clinical and demographic features were similar in the 
two groups (table 1). No patients were neutropenic (neutrophil 
Figure 1 Consolidated Standards of Reporting Trials diagram. AST, aspartate aminotransferase; GM-CSF, granulocyte-macrophage colony-
stimulating factor; ICUAI, intensive care unit- acquired infection; ITT, intention-to-treat. 
920 Pinder EM, et al. Thorax 2018;73:918–925. doi:10.1136/thoraxjnl-2017-211323
 o
n
 23 O
ctober 2018 by guest. Protected by copyright.
http://thorax.bmj.com/
Thorax: first published as 10.1136/thoraxjnl-2017-211323 on 31 July 2018. Downloaded from 
Critical care
count of <1×109/L) at baseline. Of the 17 patients randomised 
to GM-CSF, 4 received less than two doses of study drug (1 died 
before any administration of study drug and 3 triggered safety 
criteria for study drug termination (defined in the online supple-
mental data section, table S3); of these 3, 1 had thrombocytosis 
before any administration of study drug, 1 developed significant 
transaminitis after one dose, and 1 developed thrombocytopenia 
after one dose). Of the 21 patients randomised to placebo, 1 trig-
gered safety criteria for study drug termination (thrombocyto-
penia after one dose). Therefore, 13 GM-CSF-treated patients 
received at least two doses of study drug, as compared with 20 
in the placebo group.
There was a small imbalance in neutrophil phagocytosis at 
baseline, with the mean baseline phagocytosis higher in the 
group that went on to receive GM-CSF. In the results that follow, 
the data are presented with adjustment for baseline phagocytosis 
and site.
No significant difference was observed in the primary 
end point (neutrophil phagocytosis 2 days after the first dose of 
study drug, p=0.73; figure 2). The proportion of patients with 
neutrophil phagocytosis ≥50% appeared significantly higher in 
the GM-CSF group at day 2 and day 6/7, with a similar trend on 
days 4/5 and 8/9 (table 2).
The unadjusted AUC for neutrophil phagocytosis at day 9 was 
greater in the GM-CSF group (figure 3A, which also illustrates 
the small difference in baseline phagocytosis), but this did not 
reach statistical significance when adjusted for baseline phagocy-
tosis and site (p=0.14). A 9-day period was used to determine the 
natural history of neutrophil phagocytosis in the placebo group, 
and to establish whether any observed effect of GM-CSF was 
prolonged. No significant differences were apparent in neutro-
phil apoptosis (figure 3B), neutrophil chemotaxis (figure 3C) or 
superoxide generation (figure 3D). When the unadjusted primary 
outcome measure of neutrophil phagocytosis at day two was 
analysed on a per protocol basis (that is, including only patients 
receiving at least 2 doses of GM-CSF/placebo), higher neutro-
phil phagocytosis was found in the GM-CSF group but this did 
not reach statistical significance (figure 3E) when adjusted for 
baseline phagocytosis and site (p=0.50).
Low monocyte HLA-DR expression has been associated 
with acquired immunoparesis in critical illness.26–28 Monocyte 
HLA-DR was low at baseline in 26 of the 38 randomised patients. 
GM-CSF treatment appeared to be associated with a significant 
rise in monocyte HLA-DR at day 2 (p<0.01, figure 4; the data 
are shown as individual data points for each time interval in 
figure S1 in the online supplemental data section).
There were 10 deaths in the 30-day follow-up period of the 
study (6 in the placebo group, 4 in the GM-CSF group), none 
of which were considered SAEs. Details relating to deaths are 
shown in the  online supplemental data section (table S4). Three 
SAEs were described during the trial. One was in the GM-CSF 
group (intestinal obstruction requiring surgery on day 1, consid-
ered unrelated to study drug) and two in the placebo group (one 
acute respiratory deterioration with pneumomediastinum on 
day 3; one acute respiratory deterioration with type II respira-
tory failure on day 4). No suspected unexpected serious adverse 
reactions (SUSARs) were reported.
Fever was the most common adverse event recorded (four 
in the GM-CSF group, none in the placebo group). A detailed 
summary of adverse events is shown in the online supple-
mental data section (table S5). The SOFA Score was similar in 
both groups throughout the study period (online supplemental 
data section (table S6), as were the PaO2 to FiO2 ratio (online 
supplemental data section, table S7), full blood count parame-
ters (online supplemental data section, tables S8–10), urea and 
creatinine (online supplemental data section, table S11 and S12), 
and transaminases (online supplemental data section, table S13 
and S14). Circulating cytokine concentrations are shown in the 
online data supplement, figure S2.
The trial was not powered to assess differences in infection 
rates or mortality, and these parameters were analysed on a 
descriptive basis only. By day 30, 13 ICUAIs developed in six 
separate patients in the placebo group and 9 ICUAIs in seven 
separate patients in the GM-CSF group. All-cause 30-day 
mortality was 6/21 (28.6%) in the placebo group and 4/17 
(23.5%) in the GM-CSF group. When considering only patients 
who received at least two doses of trial drug, all-cause 30-day 
mortality was 30% in the placebo group (6 of 20 patients) and 
7.7% (1 of 13 patients) in the GM-CSF group.
dIsCussIon
The novelty of this study lies in only including patients whose 
neutrophil phagocytosis was known to be impaired (representing 
a group at particularly high risk of ICUAI). This cohort included 
Table 1 Baseline demographic and clinical features
Placebo GM-CsF
N 21 17
Median age, years (range) 68 (31–80) 69 (28–89)
Median body mass, kg (range) 82 (45–144) 77 (49–103)
% with a surgical reason for admission to ICU 29 18
Median APACHE II Score (IQR) 21 (18–23) 19.5 (16–27.5)
Sepsis on admission (n) 9 8
Median SOFA Score on admission (IQR) 8 (6–10) 9 (4–11)
Median lowest MAP, mm Hg (IQR) 63 (61–66) 61 (59.5–64.5)
APACHE II, Acute Physiology and Chronic Health Evaluation II; GM-CSF, granulocyte-
macrophage colony-stimulating factor; ICU, intensive care unit; SOFA, sequential 
organ failure assessment; MAP, mean arterial pressure.
Figure 2 Primary end point: neutrophil phagocytosis at day 2. 
Neutrophils were isolated from whole blood on day 2 as described 
in the Methods. Neutrophils were incubated with serum-opsonised 
zymosan particles for 30 min and the proportion ingesting two or more 
particles was determined at light microscopy. n=36 (one patient in the 
GM-CSF group died before day 2, another was withdrawn from the 
study because of thrombocytosis). Data were analysed on an intention-
to-treat basis by two-sample t-test and are shown as individual points. 
ns, p>0.05. GM-CSF, granulocyte-macrophage colony-stimulating  factor. 
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a broad spectrum of patients with causes for admission repre-
sentative of ICU case mixes. Other groups studying potential 
immunomodulatory effects of GM-CSF in critical illness have 
concentrated largely on patients with sepsis.13–16
No statistically significant difference was observed in neutro-
phil phagocytosis 2 days after the first dose of GM-CSF by 
intention-to-treat. However, we believe that the apparent signif-
icant differences in the proportion of patients with phagocy-
tosis ≥50% suggest an important biological effect of GM-CSF 
on neutrophil phagocytosis in a subset of patients (table 2). We 
chose the zymosan assay to assess neutrophil phagocytosis (and a 
cut-off of 50% for inclusion in the trial) because of our previous 
experience with the assay which, to the best of our knowledge, 
is the only neutrophil phagocytosis assay shown to predict for 
ICUAI independently in critically ill patients.11 Reassuringly, 
using this assay, the frequency of patients consented who had 
phagocytosis <50% (and therefore went on to randomisation) 
was similar to that in our previous work, which studied a similar 
cohort of patients in a different institution. Neutrophil phago-
cytosis is functionally associated with neutrophil CD88 expres-
sion,11 12 and CD88 levels (as a surrogate for phagocytosis) have 
been shown to be predictive for ICUAI.29
Our findings of higher neutrophil phagocytosis over time 
(figure 3A) in the GM-CSF group and of higher phagocytosis 
at day 2 in patients receiving at least two doses of trial drug 
(figure 3E) were both confounded by an unexpected difference 
in baseline neutrophil phagocytosis pretreatment, and were not 
statistically significantly different. However, we know of no 
biological reason or data to suggest that the effect of GM-CSF 
on neutrophils should be influenced by baseline phagocytosis. 
Indeed, GM-CSF increases phagocytosis in vitro regardless of 
baseline levels. Furthermore, despite the small difference at 
baseline, the rate of recovery of neutrophil phagocytosis appears 
greater over the 4 days of GM-CSF administration, as evidenced 
by the steepness of the slopes in figure 3A. The consistent direc-
tion of effect in the GM-CSF-treated group supports our cautious 
conclusion that there is a small but true biological response of 
GM-CSF on neutrophil function in vivo. To our knowledge 
this is the first demonstration that neutrophil phagocytosis can 
potentially be improved specifically in those critically ill patients 
in whom it is impaired, though clearly these findings require 
to be validated, and the proportion of patients likely to benefit 
most from GM-CSF requires to be carefully defined.
Enhanced neutrophil phagocytosis and the striking improve-
ment in monocyte HLA-DR (figure 4) suggest combined benefi-
cial immunomodulatory effects for GM-CSF in vivo. The close 
temporal relationship between GM-CSF administration and 
HLA-DR expression provides strong evidence, in our view, that 
GM-CSF was absorbed and biologically active. Similar GM-CSF 
blood concentrations in both groups (online supplementary 
figure S2) do not contradict this view, as blood sampling for 
cytokine estimations was performed almost a day after GM-CSF 
administration, and blood concentrations of GM-CSF generally 
return to pretreatment levels within 6–20 hours.30 31 HLA-DR 
is a good marker of immunoparesis,26 and GM-CSF has been 
shown to improve HLA-DR in critical illness.13 16 However, 
effects of GM-CSF on immunomodulatory monocyte functions 
have not been demonstrated in vivo in humans, and were not the 
focus of this study.
GM-CSF appeared to be safe in the cohort studied. GM-CSF 
delays neutrophil apoptosis, promotes adhesion to pulmonary 
endothelium in vitro, and prolongs neutrophil retention in the 
human lung,32–34 leading to the theoretical concern that it may 
promote acute respiratory distress syndrome in already criti-
cally ill patients. However this has been countered by data from 
other studies.35 36 We found no effect of GM-CSF on PaO2:FiO2 
ratios (online supplemental data section, table S7). Similarly 
we observed no effect of GM-CSF on apoptosis, chemotaxis 
or extracellular superoxide generation (figure 3). The most 
common adverse event associated with GM-CSF was fever, 
though our small sample size may not have allowed the detection 
of uncommon adverse effects.
We believe the strengths of this study lie in the ‘precision 
medicine’ approach of including patients at the greatest risk of 
ICUAI, the focus on a relevant innate immune function (rather 
than a biomarker), and the objective rigour of a multicentre, 
randomised, placebo-controlled trial in a relatively understudied 
population. However, we recognise that the study also has 
several potential limitations.
First, and most importantly, while we intended this study 
to be double-blinded, the retrospective discovery of a poten-
tial breach in blinding, related to the recording of clinical data, 
resulted in the study being reported as single-blinded. However 
we are unaware of any possibility that laboratory staff could 
have been unblinded in performing and reporting neutrophil 
assays.
Second, the number of patients recruited was relatively small. 
Based on our previous studies, we had not anticipated the rate 
of recovery in mean phagocytosis observed in the placebo 
group (figure 3A). As a consequence the study may have been 
underpowered to detect a significant difference in the primary 
end point.
The small sample size also probably explains the unexpected 
imbalance in mean neutrophil phagocytosis at baseline. In retro-
spect it could be argued that the primary end point for the 
study should have been the proportion of patients with phago-
cytosis ≥50%, given  that phagocytosis at  this  level appears  to 
confer protection against ICUAI.
Table 2 Proportion of patients with neutrophil phagocytosis ≥50%
Time point
Proportion of patients with neutrophil phagocytosis  ≥50%
P values (Fisher’s exact 
test for differences)
Placebo GM-CsF
number 
with ≥50% number in sample Per cent ≥50%
number 
with ≥50% number in sample Per cent ≥50%
Day 0 0 21 0% 0 17 0% No test done
Day 2 9 21 43% 12 15 80% 0.04
Day 4/5 7 16 44% 9 12 75% 0.14
Day 6/7 7 16 44% 10 10 100% 0.004
Day 8/9 7 11 64% 9 9 100% 0.09
GM-CSF, granulocyte-macrophage colony-stimulating  factor.
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A further limitation relates to the number of patients screened 
relative to the number recruited (figure 1). This reflected the 
requirement to make patient safety the absolute priority in a 
setting where an investigational medicinal product is being given 
to already critically ill patients. Our exclusion criteria were 
deliberately stringent, and were based on a range of potential 
adverse events associated with GM-CSF. The strict exclusion 
criteria and high screen to recruitment ratio clearly lead to 
questions over how generalisable the data are. However, it is 
perhaps reassuring that the frequency of neutrophil dysfunction 
Figure 3 Temporal changes in neutrophil phagocytosis, apoptosis, chemotaxis and superoxide generation. (A) Neutrophils were isolated from whole 
blood and phagocytosis of serum-opsonised zymosan quantified. Sample sizes (placebo/GM-CSF)—day 0 (21/17); day 2 (21/15); day 4/5 (16/12); day 
6/7 (16/10); day 8/9 (11/9). (B) Neutrophil apoptosis was assessed by flow cytometric assessment of annexin V and propidium iodide (PI). Sample sizes 
(placebo/GM-CSF)—day 0 (17/16); day 2 (17/15); day 4/5 (13/9); day 6/7 (15/10); day 8/9 (8/8). (C) Chemotaxis was assessed using the subagarose 
method to assess chemotaxis towards formyl-methionine-leucine-phenylalanine. Sample sizes (placebo/GM-CSF)—day 0 (15/12); day 2 (14/12); 
day 4/5 (9/10); day 6/7 (8/6); day 8/9 (4/3). (D) Superoxide generation was assessed using a cytochrome c reduction assay. Sample sizes (placebo/
GM-CSF)—day 0 (18/15); day 2 (17/15); day 4/5 (13/12); day 6/7 (16/10); day 8/9 (11/9). (E) Day 2 phagocytosis was assessed as for (A) above. The 
data shown are from the per protocol analysis, that is, those patients who received at least two doses of trial drug; n=33 (20 placebo, 13 GM-CSF). 
All data are shown as mean and SE. In (A) open circles=placebo, closed circles=GM-CSF; for (B)–(D), white columns=placebo, dark columns=GM-
CSF. For panel (A) statistical comparison of area under the curve for each group used the linear trapezoidal rule by summing the areas between each 
time point. In cases where there were missing data with no additional data either immediately before or after the missing time point, we did not 
calculate the area and treated that patient’s area under the curve as missing. For panels (B), (C) and (D) statistical analysis used analysis of covariance 
(ANCOVA) methods. Bonferroni's post-hoc correction was used as an informal guide to assess significance or otherwise of the resulting p values. For 
panel (E) statistical analysis was by unpaired t-test. GM-CSF, granulocyte-macrophage colony-stimulating factor. 
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and monocyte HLA-DR suppression were closely comparable to 
those described in our previous work.24 Our safety data, along 
with those from other studies of GM-CSF in critical illness, 
suggest that the stringency of exclusion criteria could be relaxed 
in future studies.
Finally, the assay used to test neutrophil phagocytosis has 
the limitation that it is labour-intensive and operator-depen-
dent, and its widespread use in hospital laboratories is hard to 
envisage. Importantly, the assay was chosen specifically because 
it predicts ICUAI in our hands, while automated assays have 
not been shown to do so thus far. Interobserver variation in the 
assay among the experienced operators in our lab was −1.04% 
(95% CI −2.82% to 0.73%). The  test was  therefore  ideal  for 
our purposes but would be harder to implement in larger studies.
In summary, this study supports a beneficial effect of GM-CSF 
on monocyte HLA-DR, and suggests a beneficial effect on 
neutrophil phagocytosis, at least in the proportion of patients 
responding. As low neutrophil phagocytosis and monocyte 
HLA-DR both predict ICUAI, and given the requirement 
to develop non-antibiotic-based strategies for prevention of 
ICUAI, we believe GM-CSF warrants evaluation in further clin-
ical studies, either alone (with or without assessment of higher 
doses), or in combination with other immune stimulants.
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